NICE seeks more information on Gilead’s Zydelig for adults with leukemia

18 June 2015

The National Institute for Health and Care Excellence (NICE), the medicines watchdog for England and Wales, has opened a consultation on preliminary draft guidance for US biotech giant Gilead Sciences’ (Nasdaq: GILD) Zydelig (idelalisib) for adults with chronic lymphocytic leukemia.

The NICE has asked for further information from the company to make a final decision on the use of idelalisib in combination with the drug rituximab for adults with chronic lymphocytic leukaemia whose disease is resistant to other treatments when it is not considered appropriate to treat again with previous therapies.

The decision is in contrast to the Scottish Medicines Consortium, which recently approved Zydelig for adult chronic lymphocytic leukemia in combination with rituximab (The Pharma Letter March 9).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology